These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

168 related articles for article (PubMed ID: 22990067)

  • 1. Effects of CYP2C19 variant alleles on postclopidogrel platelet reactivity and clinical outcomes in an actual clinical setting in China.
    Wu H; Qian J; Xu J; Sun A; Sun W; Wang Q; Ge J
    Pharmacogenet Genomics; 2012 Dec; 22(12):887-90. PubMed ID: 22990067
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Besides CYP2C19*2, the variant allele CYP2C9*3 is associated with higher on-clopidogrel platelet reactivity in patients on dual antiplatelet therapy undergoing elective coronary stent implantation.
    Harmsze A; van Werkum JW; Bouman HJ; Ruven HJ; Breet NJ; Ten Berg JM; Hackeng CM; Tjoeng MM; Klungel OH; de Boer A; Deneer VH
    Pharmacogenet Genomics; 2010 Jan; 20(1):18-25. PubMed ID: 19934793
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Genetic determinants of response to clopidogrel and cardiovascular events.
    Simon T; Verstuyft C; Mary-Krause M; Quteineh L; Drouet E; Méneveau N; Steg PG; Ferrières J; Danchin N; Becquemont L;
    N Engl J Med; 2009 Jan; 360(4):363-75. PubMed ID: 19106083
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Genetic determinants of high on-treatment platelet reactivity in clopidogrel treated Chinese patients.
    Zhang L; Chen Y; Jin Y; Qu F; Li J; Ma C; Yang J; Xu B; Wang H; Li X; Li Y; Zhang Y; Lu C; Yin T
    Thromb Res; 2013 Jul; 132(1):81-7. PubMed ID: 23726091
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Influence of CYP2C19 polymorphisms on platelet reactivity and clinical outcomes in ischemic stroke patients treated with clopidogrel.
    Qiu LN; Sun Y; Wang L; Han RF; Xia XS; Liu J; Li X
    Eur J Pharmacol; 2015 Jan; 747():29-35. PubMed ID: 25489921
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effect of CYP2C19*2 and *3 loss-of-function alleles on platelet reactivity and adverse clinical events in East Asian acute myocardial infarction survivors treated with clopidogrel and aspirin.
    Jeong YH; Tantry US; Kim IS; Koh JS; Kwon TJ; Park Y; Hwang SJ; Bliden KP; Kwak CH; Hwang JY; Gurbel PA
    Circ Cardiovasc Interv; 2011 Dec; 4(6):585-94. PubMed ID: 22045970
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effect of CYP2C19 and ABCB1 single nucleotide polymorphisms on outcomes of treatment with ticagrelor versus clopidogrel for acute coronary syndromes: a genetic substudy of the PLATO trial.
    Wallentin L; James S; Storey RF; Armstrong M; Barratt BJ; Horrow J; Husted S; Katus H; Steg PG; Shah SH; Becker RC;
    Lancet; 2010 Oct; 376(9749):1320-8. PubMed ID: 20801498
    [TBL] [Abstract][Full Text] [Related]  

  • 8. High on-treatment platelet reactivity by ADP and increased risk of MACE in good clopidogrel metabolizers.
    Marcucci R; Giusti B; Paniccia R; Gori AM; Saracini C; Valente S; Giglioli C; Parodi G; Antoniucci D; Gensini GF; Abbate R
    Platelets; 2012; 23(8):586-93. PubMed ID: 22390861
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Effect of the CYP2C19 2 and 3 genotypes, ABCB1 C3435T and PON1 Q192R alleles on the pharmacodynamics and adverse clinical events of clopidogrel in Chinese people after percutaneous coronary intervention.
    Tang XF; Wang J; Zhang JH; Meng XM; Xu B; Qiao SB; Wu YJ; Chen J; Wu Y; Chen JL; Gao RL; Yuan JQ; Yang YJ
    Eur J Clin Pharmacol; 2013 May; 69(5):1103-12. PubMed ID: 23150151
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Association of cytochrome P450 2C19 genotype with the antiplatelet effect and clinical efficacy of clopidogrel therapy.
    Shuldiner AR; O'Connell JR; Bliden KP; Gandhi A; Ryan K; Horenstein RB; Damcott CM; Pakyz R; Tantry US; Gibson Q; Pollin TI; Post W; Parsa A; Mitchell BD; Faraday N; Herzog W; Gurbel PA
    JAMA; 2009 Aug; 302(8):849-57. PubMed ID: 19706858
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Relevance of CYP2C19 2 regarding platelet reactivity in patients with acute coronary syndrome treated with clopidogrel].
    Cano P; Consuegra-Sánchez L; Conesa P; Torres-Moreno D; Jaulent L; Dau D; Picó F; Villegas M
    Med Clin (Barc); 2014 Jul; 143(1):6-12. PubMed ID: 23850044
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Influence of genetic polymorphisms on the effect of high- and standard-dose clopidogrel after percutaneous coronary intervention: the GIFT (Genotype Information and Functional Testing) study.
    Price MJ; Murray SS; Angiolillo DJ; Lillie E; Smith EN; Tisch RL; Schork NJ; Teirstein PS; Topol EJ;
    J Am Coll Cardiol; 2012 May; 59(22):1928-37. PubMed ID: 22624833
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The relationship between on-clopidogrel platelet reactivity, genotype, and post-percutaneous coronary intervention outcomes in Chinese patients.
    Tang N; Yin S; Sun Z; Xu X; Qin J
    Scand J Clin Lab Invest; 2015 May; 75(3):223-9. PubMed ID: 25594796
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Impact of the proton pump inhibitors and CYP2C19*2 polymorphism on platelet response to clopidogrel as assessed by four platelet function assays.
    Tsantes AE; Ikonomidis I; Papadakis I; Bonovas S; Gialeraki A; Kottaridi C; Kyriakou E; Kokori S; Douramani P; Kopterides P; Karakitsos P; Lekakis J; Kapsimali V
    Thromb Res; 2013 Aug; 132(2):e105-11. PubMed ID: 23830212
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Cytochrome 2C19 polymorphism and response to adjunctive cilostazol versus high maintenance-dose clopidogrel in patients undergoing percutaneous coronary intervention.
    Hwang SJ; Jeong YH; Kim IS; Park KS; Kang MK; Koh JS; Park JR; Park Y; Koh EH; Kwak CH; Hwang JY; Kim S
    Circ Cardiovasc Interv; 2010 Oct; 3(5):450-9. PubMed ID: 20823393
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The influence of omeprazole on platelet inhibition of clopidogrel in various CYP2C19 mutant alleles.
    Liu Q; Dang DS; Chen YF; Yan M; Shi GB; Zhao QC
    Genet Test Mol Biomarkers; 2012 Nov; 16(11):1293-7. PubMed ID: 23046071
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Impact of genetic variants on post-clopidogrel platelet reactivity in patients after elective percutaneous coronary intervention.
    Rideg O; Komócsi A; Magyarlaki T; Tokés-Füzesi M; Miseta A; Kovács GL; Aradi D
    Pharmacogenomics; 2011 Sep; 12(9):1269-80. PubMed ID: 21806387
    [TBL] [Abstract][Full Text] [Related]  

  • 18. CYP2C19 polymorphism and antiplatelet effects of clopidogrel in Chinese stroke patients.
    Yang J; Zhao HD; Tan J; Ding YL; Gu ZQ; Zou JJ
    Pharmazie; 2013 Mar; 68(3):183-6. PubMed ID: 23556336
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Influence of CYP2C19 polymorphisms in platelet reactivity and prognosis in an unselected population of non ST elevation acute coronary syndrome.
    Tello-Montoliu A; Jover E; Marín F; Bernal A; Lozano ML; Sánchez-Vega B; Pastor FJ; Hurtado JA; Valdés M; Vicente V; Rivera J
    Rev Esp Cardiol (Engl Ed); 2012 Mar; 65(3):219-26. PubMed ID: 22116003
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Pharmacodynamic effect of switching therapy in patients with high on-treatment platelet reactivity and genotype variation with high clopidogrel Dose versus prasugrel: the RESET GENE trial.
    Sardella G; Calcagno S; Mancone M; Palmirotta R; Lucisano L; Canali E; Stio RE; Pennacchi M; Di Roma A; Benedetti G; Guadagni F; Biondi-Zoccai G; Fedele F
    Circ Cardiovasc Interv; 2012 Oct; 5(5):698-704. PubMed ID: 23048056
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.